0001511164-14-000634.txt : 20150115 0001511164-14-000634.hdr.sgml : 20150115 20141112151236 ACCESSION NUMBER: 0001511164-14-000634 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20141112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bohai Pharmaceuticals Group, Inc. CENTRAL INDEX KEY: 0001443242 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980588402 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: C/O YANTAI BOHAI PHARMACEUTICALS GROUP STREET 2: NO. 9 DAXIN ROAD, ZHIFU DISTRICT CITY: YANTAI, SHANDONG PROVINCE STATE: F4 ZIP: 264000 BUSINESS PHONE: 86-535-6763559 MAIL ADDRESS: STREET 1: C/O YANTAI BOHAI PHARMACEUTICALS GROUP STREET 2: NO. 9 DAXIN ROAD, ZHIFU DISTRICT CITY: YANTAI, SHANDONG PROVINCE STATE: F4 ZIP: 264000 FORMER COMPANY: FORMER CONFORMED NAME: Link Resources Inc. DATE OF NAME CHANGE: 20080818 CORRESP 1 filename1.htm SEC Response Requesting Extension 11/12 (00329538).RTF

November 12, 2014



VIA EMAIL AND COURIER

Jim B. Rosenberg – Senior Assistant Chief Accountant

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549


Re:

Bohai Pharmaceuticals Group, Inc.

Form 10-K for the Fiscal Year Ended June 30, 2014 Filed October 14, 2014

File No. 000-53401


Dear Mr. Rosenberg:


Bohai Pharmaceuticals Group, Inc. (the “Company”) acknowledges receipt of the letter received from the staff (the “Staff”) of the Securities and Exchange Commission (the “SEC”) dated October 28, 2014, regarding the Company’s Form 10-K for the Fiscal Year ended June 30, 2014 (the “Form 10-K”) filed on October 14, 2014. The Company is required to respond to the Staff’s comments by Tuesday, November 12, 2014.  The Company hereby requests the opportunity to submit a response to the Staff’s comments by Tuesday, November 25, 2014 as the Company requires additional time to work internally with its staff and externally with its outside auditors and legal counsel to prepare and finalize the response.  Based on discussions between the Staff and the Company’s legal counsel, it is the Company understands that the Staff will agree to this request.


We thank the Staff in advance for its consideration of the foregoing.  Should you have any questions or comments, please contact our legal counsel, Lawrence A. Rosenbloom, Esq. or Ying Li, Esq. of Ellenoff Grossman & Schole LLP at (212) 370-1300.



Very truly yours,



/s/ Hongwei Qu

  

Hongwei Qu


 




1